Dana Kappel

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer”.

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1388

N/A

0DataRank · unranked

13 citations

Mirat Shah, Lijun Zhang, Joyce Cheng, Mary Kate Bonner, Melissa A. Pegues +22 more